H

ello, everyone, and how are you today? This morning, a warm and shiny sun is enveloping the Pharmalot campus, where things have quieted down now that the shortest of short people has left for the schoolhouse and the official mascots are happily snoozing in their recliners. As for us, we are busy foraging for interesting items and, of course, quaffing some cups of stimulation. Feel free to join in. Meanwhile, here is the latest menu of tidbits. We hope you have a grand day or, at least, survive. And if you do, by all means, keep in touch …

A U.S. administrative court invalidated a Johnson & Johnson (JNJ) patent on its blockbuster Zytiga prostate cancer drug, bringing rivals closer to selling generic versions, Reuters informs us. The ruling was a victory for Argentum Pharmaceuticals, which had asked the U.S. Patent Trial and Appeal Board to invalidate the patent in hopes of bringing its own version to market.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.